Capricor Therapeutics, Inc.
- CAPR
- NASDAQ
- Biotechnology
- Cell & Exosome Therapy
- Duchenne Muscular Dystrophy
$6.65
Today −0.89%Quote Oct 19, 2026, 08:00 PM UTC
−28.77%over the last month
Max drawdown −30.4%From 1-month high −29.1%3 months −65.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
231
Market value
$385.1M
Quote Oct 19
Floor
$6.57
1.2% below price
Resistance
$6.74
1.3% above price
Price vs analyst targets
10 analysts
Lowest target
$3.50Highest target
$25.00
$3.50Highest target
$25.00
- Price $6.65
- Average target $12.70
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 91% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CAPRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free